Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436289 | 0.92 | ALDH1A1 (0.51) | ALDH1A1TSHRHTTSMN1; SMN2USP2 | |
| SCHEMBL3436286 | 0.86 | MAPK1 (0.52) | ALDH1A1TSHRHTTSMN1; SMN2USP2 | |
| SCHEMBL3556537 | 0.82 | ALDH1A1 (0.44) | ALDH1A1TSHRHTTSMN1; SMN2MEN1 | |
| SCHEMBL3436302 | 0.82 | TSHR (0.66) | ALDH1A1TSHRHTTSMN1; SMN2USP2 | |
| SCHEMBL3436299 | 0.80 | ALDH1A1 (0.51) | ALDH1A1TSHRHTTSMN1; SMN2MEN1 | |
| SCHEMBL3436490 | 0.80 | ALDH1A1 (0.49) | ALDH1A1TSHRHTTSMN1; SMN2MEN1 | |
| SCHEMBL3436298 | 0.80 | ALDH1A1 (0.64) | ALDH1A1TSHRHTTSMN1; SMN2USP2 | |
| SCHEMBL3436304 | 0.78 | POLB (0.48) | ALDH1A1TSHRHTTSMN1; SMN2USP2 | |
| SCHEMBL3436291 | 0.78 | ITGB3 (0.43) | HTTITGB3ITGA2BUSP2ATM | |
| SCHEMBL8744982 | 0.77 | HTT (0.59) | ALDH1A1TSHRHTTSMN1; SMN2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | ALDH1A1 975/4885TSHR 867/4885HTT 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.